This page has been robot translated, sorry for typos if any. Original content here.

Attention! The information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Description of the medicine: Reumycin (Reumycinum)

REUMICIN (Reumycinum).

Antitumor compound derived from xanthotricin produced by Actinomyces rectus bruneus subsp. xanthothricini. 6, 8-dihydro-6-methyl-pyrimido [5, 6th] - 1, 2, 4-triazine-5, 7-dione.

The crystalline powder is yellow. Slowly and slightly soluble in water. Sensitive to light.

It has antitumor activity, mainly in malignant neoplasms (gliomas, etc.) of the brain. Usually used after surgical removal of the tumor in the absence of postoperative complications. Treatment begins 7 to 8 days after surgery.

Injection solution is prepared immediately before use. Enter endolumbally and (or) intravenously. For endolumbar administration, the contents of the vial are dissolved - 0.02 g (20 mg) in 10 ml of isotonic sodium chloride solution; for intravenous administration, 0.01 g (100 mg) - 200 ml of isotonic sodium chloride or 5% solution is added to the contents of the vial. glucose.

Start with endolumbal administration of 2.5 mg or intravenous administration of 100 mg. With good tolerance, doses are gradually increased to 5–10 mg or 200–300 mg, respectively.

Endolumbal injections are made every 48 hours to a total dose of 0.05 g (50 mg). A vein is injected daily for 10 to 12 days to a total dose of 1 to 2 g.

Repeated courses are carried out after 2 - 2, 5 months.

Reumitsin can be used independently and in combination with other means and methods of treating brain tumors.

When using rumicin, nausea, vomiting, headache, and fever may occur. With intravenous administration, ECG changes can be observed, in these cases, reduce the dose or stop the administration of the drug.

Contraindications to the use of rumicin are severe arterial hypertension, severe diseases of the myocardium, kidneys, liver, diabetes mellitus, inflammatory postoperative complications, and a tendency to allergic reactions.

Release form: in the form of a yellow porous mass of 0.02 g (20 mg) in 10 ml bottles and 0.1 g (100 mg) in 25 ml bottles in a package of 20; 40 and 50 bottles.

Storage: List A. In the dark place at a temperature of no higher than + 10 C.